| dc.creator | Lima M., Aloizou A.-M., Siokas V., Bakirtzis C., Liampas I., Tsouris Z., Bogdanos D.P., Baloyannis S.J., Dardiotis E. | en |
| dc.date.accessioned | 2023-01-31T08:55:11Z | |
| dc.date.available | 2023-01-31T08:55:11Z | |
| dc.date.issued | 2022 | |
| dc.identifier | 10.1515/revneuro-2021-0148 | |
| dc.identifier.issn | 03341763 | |
| dc.identifier.uri | http://hdl.handle.net/11615/75928 | |
| dc.description.abstract | The purpose of this review is to examine whether there is a possible (etiological/triggering) relationship between infection with various Coronaviruses, including Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2), the virus responsible for the Coronavirus disease-19 (Covid-19) pandemia, and Multiple Sclerosis (MS), and whether an increase of the prevalence of MS after the current Covid-19 pandemia should be expected, examining new and preexisting data. Although the exact pathogenesis of MS remains unknown, environmental agents seem to greatly influence the onset of the disease, with viruses being the most popular candidate. Existing data support this possible etiological relationship between viruses and MS, and experimental studies show that Coronaviruses can actually induce an MS-like demyelinating disease in animal models. Findings in MS patients could also be compatible with this coronaviral MS hypothesis. More importantly, current data from the Covid-19 pandemia show that SARS-CoV-2 can trigger autoimmunity and possibly induce autoimmune diseases, in the Central Nervous System as well, strengthening the viral hypothesis of MS. If we accept that Coronaviruses can induce MS, it is reasonable to expect an increase in the prevalence of MS after the Covid-19 pandemia. This knowledge is of great importance in order to protect the aging groups that are more vulnerable against autoimmune diseases and MS specifically, and to establish proper vaccination and health policies. © 2022 Maria Lima et al., published by De Gruyter, Berlin/Boston. | en |
| dc.language.iso | en | en |
| dc.source | Reviews in the Neurosciences | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126528185&doi=10.1515%2frevneuro-2021-0148&partnerID=40&md5=e2a16caf52971baff6ae06d1914e57b4 | |
| dc.subject | autoantibody | en |
| dc.subject | epitope | en |
| dc.subject | SARS-CoV-2 vaccine | en |
| dc.subject | superantigen | en |
| dc.subject | aging | en |
| dc.subject | antibody blood level | en |
| dc.subject | Article | en |
| dc.subject | autoimmune disease of the central nervous system | en |
| dc.subject | autoimmunity | en |
| dc.subject | brain tissue | en |
| dc.subject | bystander effect (cell) | en |
| dc.subject | cerebrospinal fluid analysis | en |
| dc.subject | Coronavirinae | en |
| dc.subject | coronavirus disease 2019 | en |
| dc.subject | data analysis | en |
| dc.subject | demyelinating disease | en |
| dc.subject | demyelination | en |
| dc.subject | disease activity | en |
| dc.subject | disease association | en |
| dc.subject | disease course | en |
| dc.subject | disease model | en |
| dc.subject | disease risk assessment | en |
| dc.subject | environmental factor | en |
| dc.subject | evidence based medicine | en |
| dc.subject | experimental study | en |
| dc.subject | health care policy | en |
| dc.subject | human | en |
| dc.subject | hypothesis | en |
| dc.subject | leukocyte count | en |
| dc.subject | multiple sclerosis | en |
| dc.subject | nonhuman | en |
| dc.subject | pandemic | en |
| dc.subject | pathophysiology | en |
| dc.subject | prevalence | en |
| dc.subject | prophylaxis | en |
| dc.subject | risk factor | en |
| dc.subject | Severe acute respiratory syndrome coronavirus 2 | en |
| dc.subject | vaccination | en |
| dc.subject | vulnerable population | en |
| dc.subject | animal | en |
| dc.subject | multiple sclerosis | en |
| dc.subject | pandemic | en |
| dc.subject | prevalence | en |
| dc.subject | Animals | en |
| dc.subject | COVID-19 | en |
| dc.subject | Humans | en |
| dc.subject | Multiple Sclerosis | en |
| dc.subject | Pandemics | en |
| dc.subject | Prevalence | en |
| dc.subject | SARS-CoV-2 | en |
| dc.subject | De Gruyter Open Ltd | en |
| dc.title | Coronaviruses and their relationship with multiple sclerosis: is the prevalence of multiple sclerosis going to increase after the Covid-19 pandemia? | en |
| dc.type | journalArticle | en |